Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $798,976.97 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Patrick Harrison Carroll sold 23,287 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $34.31, for a total transaction of $798,976.97. Following the completion of the transaction, the insider now directly owns 209,661 shares in the company, valued at $7,193,468.91. This represents a 10.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $32.85 on Friday. The stock’s 50-day moving average is $39.02 and its two-hundred day moving average is $28.55. The stock has a market cap of $7.30 billion, a PE ratio of 74.67 and a beta of 1.37. Hims & Hers Health, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. On average, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

HIMS has been the topic of several recent research reports. Piper Sandler raised their price target on Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, February 25th. Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price target for the company from $42.00 to $60.00 in a report on Tuesday, February 18th. Bank of America increased their price objective on shares of Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a report on Tuesday. Citigroup reiterated a “sell” rating and issued a $27.00 price objective on shares of Hims & Hers Health in a research report on Thursday, March 6th. Finally, Canaccord Genuity Group upped their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $37.31.

Institutional Trading of Hims & Hers Health

Several hedge funds and other institutional investors have recently modified their holdings of HIMS. California State Teachers Retirement System grew its stake in Hims & Hers Health by 18.8% in the fourth quarter. California State Teachers Retirement System now owns 166,337 shares of the company’s stock valued at $4,022,000 after purchasing an additional 26,363 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at about $213,000. IronOak Wealth LLC. bought a new stake in shares of Hims & Hers Health in the 4th quarter valued at approximately $922,000. Kilter Group LLC acquired a new position in Hims & Hers Health in the fourth quarter worth approximately $1,053,000. Finally, Cim LLC raised its position in Hims & Hers Health by 1.0% during the fourth quarter. Cim LLC now owns 71,869 shares of the company’s stock valued at $1,738,000 after acquiring an additional 694 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.